Search Results
May 21, 2026, 08:33 ET New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System
137.9 mg/dL139.5 mg/dLTime
More news about: MiniMed
May 21, 2026, 06:45 ET Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
retatrutide 4 mg, 9 mg, 12 mg, or placebo. Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a step-wise approach every four weeks until reaching the target dose of 4 mg (via one step at 2 mg), 9 mg (via steps at 2 mg, 4 mg and 6 mg) or 12 mg (via steps
More news about: Eli Lilly and Company
May 20, 2026, 12:48 ET /C O R R E C T I O N -- Pegasus/PRN Pharmacal/
approval, providing veterinarians with access to this therapy sooner. Liavium-CA1 is slated to be available in 30 mg, 90 mg, and 180 mg beef-flavored chewable tablet strengths (the 90 mg tablet is scored for splitting) to accommodate dogs weighing approximately 6.6 to 50 pounds, by prescription from
More news about: Pegasus/PRN Pharmacal
May 20, 2026, 09:50 ET Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
across multiple inflammatory biomarkers, with a favorable tolerability profile.Notably, the 60 mg dose achieved hsCRP and other biomarker reductions comparable to the previously reported 120 mg dose. Based on the full Phase 1 dataset, BioAge intends to initiate a dose-ranging Phase 2 cardiovascular
More news about: Market News Updates
May 20, 2026, 09:21 ET Remepy Reports Strong Clinical Phase IIa Results for Hybridopa™, a First-in-Class Hybrid Drug for Parkinson's Disease
trial (N=41) evaluated Hybridopa in patients aged 45–80 with Parkinson's disease. Participants were all on an unchanged dose of levodopa (ranging 150-1500mg daily), combined with DopApp™ or with a placebo digital application. The intervention consisted of a multi-modal daily digital protocol enabling structured,
More news about: Remepy
May 20, 2026, 09:05 ET Quest Products Launches OraHealth Antacid Melts, the First Stick-On Antacid for Nighttime Heartburn Relief
stimulates saliva production, helping activate the body's natural first line of defense against heartburn and acid reflux. Then, it slowly releases 250 mg of calcium carbonate over time to help neutralize stomach acid and provide relief that lasts for hours.Unlike traditional antacids that may be
More news about: Quest Products
May 20, 2026, 08:34 ET Death Wish Coffee Co. Unleashes Power Surge, A Naturally Higher Caffeinated Roast, Boasting More Than 200 mg of Caffeine Per Serving
beans. Death Wish Coffee has always leveraged the resilient Robusta bean, which boasts naturally higher caffeine levels (around 2.5 mg per bean compared to Arabica's 1.5 mg) to deliver clean caffeine that calms the chaos. This full-bodied brew features low acidity and a bold taste profile of berry and malt,
More news about: Death Wish Coffee Co.
May 20, 2026, 08:08 ET Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
hepatic impairment. Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment.LENVIMA (lenvatinib) is available as 10 mg and 4 mg capsules.Please see Prescribing Information for LENVIMA (lenvatinib) at
More news about: Eisai Inc.
May 19, 2026, 15:14 ET BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data
reported from the Bimekizumab Total group (BKZ Total), which includes those receiving BIMZELX 160 mg every four weeks (Q4W) in those with no or mild psoriasis (n=248), and those receiving BIMZELX 320 mg every four weeks to Week 16 and then every eight weeks thereafter (Q4W/Q8W) in those with moderate
More news about: UCB
May 19, 2026, 08:00 ET Dechra Announces FDA Approval of CosACTHen® (cosyntropin injection), the First and Only Cosyntropin Approved Specifically for Canine Patients
of CosACTHen®:Indication & Use: Indicated for the evaluation of adrenal function in dogs. Available as a 0.25 mg/ml solution in 1 ml single-use vials.ACTH Stimulation Testing: CosACTHen® is integral to ACTH stimulation tests, the
More news about: Dechra
May 19, 2026, 06:15 ET Epson Introduces New Laser Display Lineup Designed for Greater Impact, Simplicity and Flexibility Across Any Space
hours (Normal Mode). Approximate time until brightness decreases 50% from first usage. Measured by acceleration test assuming use of 0.04 - 0.20 mg/m3 of particulate matter. Time varies depending on usage conditions and environment. Replacement of parts other than the light source may be required
More news about: Epson America, Inc.
May 18, 2026, 16:51 ET Sun Home Luminar Named Best Overall Outdoor Sauna of 2026 in homesauna.com Buyer's Guide
commonly cited in published infrared sauna research.Named-lab EMF testing. Tested by Vitatech Electromagnetics (January 2025) at 0.5 mG in the seated position using fluxgate magnetometers.Published VOC testing. Tested by VERT Environmental (San Diego) and LA Testing (Huntington
More news about: homesauna.com
May 18, 2026, 16:05 ET Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic
More news about: Neurocrine Biosciences, Inc.
May 18, 2026, 09:08 ET Unionfab Reduces Low-Volume Metal Parts Production from 30 Days to as Fast as 5 Days
density and consistent surface quality.Unionfab supports various industrial-grade materials, including stainless steel (316L, 17-4PH), aluminum (AlSi10Mg, Al6061, Al901X), titanium (TC4), CuCrZr and Inconel (625, 718) etc. Its self-developed aerospace-grade high-strength aluminum alloy Al901X combines
More news about: Unionfab
May 18, 2026, 09:00 ET INSTYTUTUM Launches a Next-Generation NMN Supplement and At-Home Biological Age Test -- A Biotech Breakthrough in Cellular Health and Longevity
THE INSTYTUTUM LONGEVITY SUPPLEMENT ($100) combines 500 mg Liposomal NMN and 500 mg Micronized Trans-Resveratrol — engineered to support your NAD⁺ levels, cellular energy, mental clarity, physical performance, metabolic health,
More news about: INSTYTUTUM
May 18, 2026, 08:31 ET MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.About Vanoglipel (DA-1241)Vanoglipel
More news about: MetaVia Inc.
May 18, 2026, 08:05 ET FDA Approves IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi), First Biosimilars to Simponi® (golimumab) and Simponi Aria® (golimumab); Accord BioPharma to Lead U.S. Commercialization
www.fda.gov/medwatch.IMMGOLIS (golimumab-sldi) injection is supplied in a 50 mg/0.5 mL and 100 mg/mL single-dose prefilled syringe.IMMGOLIS INTRI (golimumab-sldi) injection is supplied in a 50 mg/4 mL (12.5 mg/mL) solution in a single-dose vial.Click here for
More news about: Accord BioPharma
May 18, 2026, 08:00 ET Bang Energy Launches American Berry - A Bold New Flavor Celebrating 250 Years of America
experimentation.Like Purple Haze, Lime Pop Drop, Peach Mango and the rest of the Bang family, each 16-oz. can of American Berry energizes with 300 mg of caffeine and contains zero sugar and zero calories, along with Ultra CoQ10 and essential aminos, powering the "READY SET BANG" ethos.Whether
More news about: Bang Energy
May 18, 2026, 08:00 ET U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
(NCT06215820).Both Phase 3 trials evaluated the efficacy and safety of fast-acting meloxicam versus placebo and included an opioid arm (tramadol 50mg q6h) to confirm the sensitivity of the pain model. The primary endpoint in both trials was defined by the Sum of Pain Intensity Difference (SPID) based
More news about: Viatris Inc.
May 18, 2026, 08:00 ET Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
evaluation. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.Pneumonitis/Interstitial lung disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated
More news about: Astellas Pharma Inc.
May 18, 2026, 07:32 ET Samson Clinical Announces Last Patient Last Visit in its Pivotal Phase III Study of Sublingual Minoxidil for Male Androgenetic Alopecia
results are expected in Q2 2026.SAM-002 is a 24-week, multicentre, double-blind, placebo-controlled study investigating a rapid dissolving 2.5 mg minoxidil tablet, administered sublingually twice daily. The primary endpoint is the mean change in the Target Area Hair Count.Sublingual minoxidil
More news about: Samson Clinical Operations Pty Ltd
May 18, 2026, 07:00 ET Triquetra Health Launches FolinicActive™--First Multi-Pathway Active Folate with Complete Tri-Cofactor System
daily) and a vegan capsule (60 count, 1 capsule daily). Both deliver identical active ingredients at identical doses—1 mg folinic acid, 1,000 mcg B-12 tri-blend, 5 mg P-5-P, and 2 mg R-5-P—enabling flexible format selection without any change in formulation. The liquid and capsule products are manufactured
More news about: Triquetra Health LLC
May 18, 2026, 07:00 ET Triquetra Health Launches FolinicActive™ Adult Liquid--First Multi-Pathway Active Folate with Complete Tri-Cofactor System
Liquid delivers 1 mg folinic acid (as calcium folinate) per 0.50 mL serving alongside the Complete Tri-Cofactor System: 1,000 mcg Vitamin B-12 as a tri-blend (80% methylcobalamin, 10% adenosylcobalamin, 10% hydroxocobalamin), 5 mg active B-6 as pyridoxal-5′-phosphate (P-5-P), and 2 mg active B-2 as riboflavin-5′-phosphate
More news about: Triquetra Health LLC
May 18, 2026, 07:00 ET Apnimed Announces Publication of its Phase 3 SynAIRgy Trial of AD109 for Obstructive Sleep Apnea in the American Journal of Respiratory and Critical Care Medicine
of sleep-related breathing diseases, today announced the simultaneous publication of two peer-reviewed articles on AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg), an investigational, once-daily oral pill taken at bedtime designed to improve oxygenation and target the neuromuscular root cause of obstructive
More news about: Apnimed, Inc.
May 18, 2026, 07:00 ET Triquetra Health Launches Instant Aminos--First Free-Form EAA Tablets Delivering All 9 Essential Amino Acids with Zero Bloating
blender, no bloating means it actually fits your life. This is protein support built around how people want to live."Instant Aminos features a 4,000mg Amino Acid Complex per 4-tablet serving, including L-Leucine, L-Lysine Acetate, L-Valine, L-Isoleucine, L-Threonine, L-Phenylalanine, L-Methionine,
More news about: Triquetra Health LLC